co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Gaja Capital IPO | The home-grown alternative asset management company will issue fresh shares worth Rs 549.2 crore, while existing shareholders including promoters will be offloading Rs 107 crore via offer-for-sale.
IndiGo share price: DGCA has withdrawn a rule than barred airlines from substituting weekly rest with leave, after IndiGo's massive flight cancellations.
IndiGo share price: IndiGo has cancelled all domestic flights departing from Delhi until midnight. The total number of cancellations in recent days has now crossed 1,000.
Vidya Wires IPO GMP: Vidya Wires launched its IPO earlier this week to raise over Rs 300 crore at a price band of Rs 48-52 per share.
Aequs IPO GMP: The Rs 922-crore IPO received bids for over 427 crore shares, as against the offer size of 4.20 crore shares.
Moore Threads' share frenzy stands out in an otherwise sluggish market, signaling strong investor appetite in specific sectors like this year’s AI winners.
Kaynes Technology share price: The shares have extended significant losses for the second day after Kotak Institutional Equities raised concerns over inconsistencies in the company's related-party disclosures.
SKF India (Industrial) share price: Earlier in 2024, SKF India's board had approved a plan to demerge its automotive business from its industrial segment. The demerger became effective on October 1.
HUL demerger: Listing of the demerged Kwality Wall's India shares will be undertaken in due course of time.
Park Medi World has reduced its IPO size from Rs 1,260 crore planned earlier as per the DRHP, which was comprised of fresh issue of Rs 960 crore worth shares, and an offer-for-sale of Rs 300 crore.
BAT is the second-biggest shareholder in ITC Hotels. It inherited the stake through its shareholding in ITC, which spun off its hotels business in January.
The court held that the trust failed to comply with Sections 50 and 51 of the MPT Act, which require prior approval for suits involving trustees and public trust property.
Analysts expect the underperformance of rupee to continue in the near term, especially if crude oil prices stay elevated and foreign investors remain risk-averse.
Ashok Hinduja told The Economic Times that IndusInd International Holdings (IIHL) is looking for a strategic partner with global expertise who wants to come in as a minority investor in IndusInd Bank.
Vidya Wires IPO GMP: Vidya Wires launched its IPO to raise over Rs 300 crore at a price band of Rs 48-52 per share
Meesho IPO GMP: While the GMP has slightly fallen recently, it still indicates a strong listing for the e-commerce platform.
Petronet LNG share price: Nomura sees this announcement as a positive development. The international brokerage kept a 'Buy' call on the stock, with a target price implying an upside potential of nearly 34%.
IndiGo share price: The shares dropped to Rs 5,405 apiece in the morning, the lowest level seen by the stock in more than five months.
Corona Remedies IPO | The company has revised its IPO size to Rs 655.37 crore, lower than the Rs 800 crore initially planned at the time of submitting draft papers in late April.
Nephrocare Health Services IPO | The company aims to raise Rs 353.4 crore by issuing fresh shares, while promoters and investors will be selling up to 1.12 crore equity shares via offer-for-sale.
The US biosimilars market is projected to balloon from about $22.6 billion in 2025 to more than $90 billion by 2034, according to industry estimates.
The rupee crossed the 90-mark against the US dollar on persistent outflows and uncertainty around the India-US trade deal
Tata Communications share price: Macquarie kept a ‘Buy’ call on the stock, with a target price of Rs 2,210 per share. This implies an upside potential of nearly 20% from the stock’s previous closing price.
Aequs IPO GMP: Aequs launched its IPO to raise around Rs 922 crore through a fresh issue of shares worth Rs 670 crore and an OFS of shares worth Rs 251.81 crore.
The company, however, cannot sell the drug in the country till March 2026, when Novo Nordisk’s secondary patent expires
